SEC Info - Codexis, Inc. - ‘10-Q’ for 9/30/21

SEC Info℠

Home

Help

Please Sign In

Codexis, Inc. – ‘10-Q’ for 9/30/21 – ‘EX-10.1’

On: Friday, 11/5/21, at 4:28pm ET · For: 9/30/21 · Accession #: 1200375-21-56 · File #: 1-34705

  As Of               Filer                 Filing    For·On·As Docs:Size

11/05/21  Codexis, Inc.                     10-Q        9/30/21   84:8.8M

Quarterly Report — Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.00M 
 2: EX-10.1     Material Contract                                   HTML     57K 
 3: EX-10.2     Material Contract                                   HTML     35K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     28K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     25K 
13: R1          Cover Page                                          HTML     76K 
14: R2          Condensed Consolidated Balance Sheets (Unaudited)   HTML    152K 
15: R3          Condensed Consolidated Balance Sheets (Unaudited)   HTML     42K 
                (Parenthetical)                                                  
16: R4          Condensed Consolidated Statements of Operations     HTML     93K 
                (Unaudited)                                                      
17: R5          Condensed Consolidated Statements of Stockholders'  HTML     79K 
                Equity (Unaudited)                                               
18: R6          Condensed Consolidated Statements of Cash Flows     HTML    119K 
                (Unaudited)                                                      
19: R7          Description of Business                             HTML     49K 
20: R8          Basis of Presentation and Summary of Significant    HTML     40K 
                Accounting Policies                                              
21: R9          Revenue Recognition                                 HTML    124K 
22: R10         Net Income (loss) per Share                         HTML     51K 
23: R11         Investments in Non-Marketable Securities            HTML     39K 
24: R12         Fair Value Measurements                             HTML     43K 
25: R13         Balance Sheets Details                              HTML     64K 
26: R14         Stock-based Compensation                            HTML     64K 
27: R15         Capital Stock                                       HTML     33K 
28: R16         Commitments and Contingencies                       HTML     86K 
29: R17         Related Party Transactions                          HTML     32K 
30: R18         Segment, Geographical and Other Revenue             HTML    170K 
                Information                                                      
31: R19         Allowance for Credit Losses                         HTML     48K 
32: R20         Basis of Presentation and Summary of Significant    HTML     50K 
                Accounting Policies (Policies)                                   
33: R21         Revenue Recognition (Tables)                        HTML    123K 
34: R22         Net Income (loss) per Share (Tables)                HTML     51K 
35: R23         Investments in Non-Marketable Securities (Tables)   HTML     35K 
36: R24         Fair Value Measurements (Tables)                    HTML     43K 
37: R25         Balance Sheets Details (Tables)                     HTML     69K 
38: R26         Stock-based Compensation (Tables)                   HTML     55K 
39: R27         Commitments and Contingencies (Tables)              HTML     76K 
40: R28         Segment, Geographical and Other Revenue             HTML    170K 
                Information (Tables)                                             
41: R29         Allowance for Credit Losses (Tables)                HTML     49K 
42: R30         Description of Business (Details)                   HTML     40K 
43: R31         Revenue Recognition - Disaggregation of Revenue     HTML     58K 
                (Details)                                                        
44: R32         Revenue Recognition - Contracts with Customer       HTML     32K 
                (Details)                                                        
45: R33         Revenue Recognition - Narrative (Details)           HTML     26K 
46: R34         Revenue Recognition - Revenue Recognized During     HTML     35K 
                Period (Details)                                                 
47: R35         Revenue Recognition - Performance Obligation        HTML     54K 
                (Details)                                                        
48: R36         Net Income (loss) per Share - Earnings Per Share    HTML     58K 
                (Details)                                                        
49: R37         Net Income (loss) per Share - Shares Not Included   HTML     29K 
                in Computation of Diluted Net Income (Loss) Per                  
                Share (Details)                                                  
50: R38         Investments in Non-Marketable Securities -          HTML     62K 
                Narrative (Details)                                              
51: R39         Investments in Non-Marketable Securities -          HTML     33K 
                Carrying Value and Fair Value of Securities                      
                (Details)                                                        
52: R40         Fair Value Measurements (Details)                   HTML     48K 
53: R41         Balance Sheets Details - Cash and Cash Equivalents  HTML     33K 
                (Details)                                                        
54: R42         Balance Sheets Details - Inventories (Details)      HTML     34K 
55: R43         Balance Sheets Details - Property and Equipment,    HTML     48K 
                net (Details)                                                    
56: R44         Balance Sheets Details - Goodwill (Details)         HTML     26K 
57: R45         Balance Sheets Details - Other Accrued Liabilities  HTML     33K 
                (Details)                                                        
58: R46         Stock-based Compensation - Equity Incentive Plans   HTML     32K 
                (Details)                                                        
59: R47         Stock-based Compensation - Stock Options (Details)  HTML     51K 
60: R48         Stock-based Compensation - Restricted Stock Units   HTML     33K 
                (Details)                                                        
61: R49         Stock-based Compensation - PSUs and PBOs (Details)  HTML     54K 
62: R50         Stock-based Compensation - Stock-based              HTML     47K 
                Compensation Expense (Details)                                   
63: R51         Capital Stock (Details)                             HTML     46K 
64: R52         Commitments and Contingencies - Narrative           HTML    110K 
                (Details)                                                        
65: R53         Commitments and Contingencies - Lease Cost          HTML     49K 
                (Details)                                                        
66: R54         Commitments and Contingencies - Other Lease         HTML     28K 
                Information (Details)                                            
67: R55         Commitments and Contingencies - Cash Paid for       HTML     28K 
                Lease Obligations (Details)                                      
68: R56         Commitments and Contingencies - Maturity Analysis   HTML     42K 
                of Operating Lease (Details)                                     
69: R57         Commitments and Contingencies - Estimated Maturity  HTML     42K 
                Analysis (Details)                                               
70: R58         Commitments and Contingencies - Other Commitments   HTML     31K 
                (Details)                                                        
71: R59         Related Party Transactions - Molecular Assemblies,  HTML     66K 
                Inc. (Details)                                                   
72: R60         Related Party Transactions - AstraZeneca PLC        HTML     34K 
                (Details)                                                        
73: R61         Segment, Geographical and Other Revenue             HTML     28K 
                Information - Narrative (Details)                                
74: R62         Segment, Geographical and Other Revenue             HTML     89K 
                Information - Segment Reporting (Details)                        
75: R63         Segment, Geographical and Other Revenue             HTML     50K 
                Information - Concentration Risk (Details)                       
76: R64         Segment, Geographical and Other Revenue             HTML     36K 
                Information - Revenues by Geographic Area                        
                (Details)                                                        
77: R65         Segment, Geographical and Other Revenue             HTML     27K 
                Information - Long-Lived Assets by Geographic Area               
                (Details)                                                        
78: R66         Segment, Geographical and Other Revenue             HTML     33K 
                Information - Goodwill (Details)                                 
79: R67         Allowance for Credit Losses - Analysis of           HTML     26K 
                Allowance for Credit Losses (Details)                            
80: R68         Allowance for Credit Losses - Summary of Finance    HTML     35K 
                Receivables by Aging Category (Details)                          
82: XML         IDEA XML File -- Filing Summary                      XML    151K 
12: XML         XBRL Instance -- cdxs-20210930_htm                   XML   2.45M 
81: EXCEL       IDEA Workbook of Financial Reports                  XLSX    101K 
 8: EX-101.CAL  XBRL Calculations -- cdxs-20210930_cal               XML    161K 
 9: EX-101.DEF  XBRL Definitions -- cdxs-20210930_def                XML    639K 
10: EX-101.LAB  XBRL Labels -- cdxs-20210930_lab                     XML   1.49M 
11: EX-101.PRE  XBRL Presentations -- cdxs-20210930_pre              XML    946K 
 7: EX-101.SCH  XBRL Schema -- cdxs-20210930                         XSD    155K 
83: JSON        XBRL Instance as JSON Data -- MetaLinks              378±   533K 
84: ZIP         XBRL Zipped Folder -- 0001200375-21-000056-xbrl      Zip    316K

‘EX-10.1’ — Material Contract

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

<! C: C:

Document


[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed

Exhibit 10.1

AMENDMENT NO. 5 TO SITAGLIPTIN SUPPLY AGREEMENT

AMENDMENT NO. 5 TO SITAGLIPTIN CATALYST SUPPLY AGREEMENT (this “AMENDMENT”) is effective as of July 1, 2021 (the “AMENDMENT EFFECTIVE DATE”) by and between Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, CA 94063 (“CODEXIS”) and Merck Sharp and Dohme Corp., having a place of business at One Merck Drive, Whitehouse Station, NJ 08889-0100. (“MERCK”)

W I T N E S S E T H:

WHEREAS, the parties are party to that certain SITAGLIPTIN CATALYST SUPPLY AGREEMENT dated as of February 1, 2012, as amended as of October 1, 2013, February 25, 2015, December 4, 2015 and as of January 1, 2016 (as so amended, the “AGREEMENT”); and

WHEREAS, the parties desire to amend the AGREEMENT to modify the terms of the AGREEMENT as more fully set forth below;

NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows:

1.As of the AMENDMENT EFFECTIVE DATE, the AGREEMENT is amended as follows:

1.01Section 2.1.2 shall be amended to read in its entirety as follows:

During the TERM of this AGREEMENT, CODEXIS shall be the supplier of a minimum of [***]% of the SUBSTANCE requirements by MERCK; provided, however, there are no supply disruptions or compliance issues with the CODEXIS supplied SUBSTANCE pursuant to this Section 2.1.2. In the event MERCK or CODEXIS identifies a SUBSTANCE compliance issue with respect to the quality of SUBSTANCE or if CODEXIS is unable to supply, or anticipates it will be unable to supply, in whole or in part, the quantity of SUBSTANCE to MERCK as set forth in any purchase order or forecast, the identifying PARTY shall notify the other PARTY immediately of such issue, and the PARTIES shall discuss such issue in good faith. If the PARTIES mutually agree that such issue creates a significant risk with respect to quality and/or DELIVERY of SUBSTANCE, the PARTIES shall discuss in good faith steps to be taken to resolve such issue and CODEXIS shall have thirty (30) days to resolve such issue. If CODEXIS is unable to resolve such issue within such thirty (30)-day period, then MERCK shall have the right to immediately qualify its own SUBSTANCE MANUFACTURER and/or purchase from its own direct SUBSTANCE MANUFACTURER any quantity sufficient to alleviate the shortage and CODEXIS will have the obligation to immediately provide the appropriate technical support for such qualification at no cost to MERCK. In this case, the [***]% minimum SUBSTANCE supply commitment to CODEXIS by MERCK will immediately cease to be in effect until CODEXIS resolves such SUBSTANCE compliance issue to MERCK's reasonable satisfaction, at which point, such [***]% minimum requirement shall be reinstated at a reasonable time as MERCK may have made commitments to other suppliers to mitigate the risk. CODEXIS also hereby agrees and acknowledges that in the event of a shortage of SUBSTANCE, all available quantities of SUBSTANCE shall be allocated for DELIVERY to MERCK and shall be used solely to satisfy CODEXIS’ obligations to MERCK hereunder prior to satisfying CODEXIS’ obligations to any other customer besides MERCK.

1.02Section 2.1.3 shall be amended to read in its entirety as follows:

“Beginning on February 1, 2022, MERCK, its AFFILIATES, and its THIRD PARTY SUPPLIER have the right to purchase up to and including [***]% of SUBSTANCE demand directly from a direct SUBSTANCE MANUFACTURER. The direct SUBSTANCE MANUFACTURER will be [***], which is also the SECONDARY SUBSTANCE MANUFACTURER for CODEXIS.

MERCK will negotiate the price for such SUBSTANCE directly with [***] and CODEXIS will not be involved in any part of the commercial agreement.

Within ninety (90) days after delivery of SUBSTANCE by [***] (as MERCK's, its AFFILIATES', and its THIRD PARTY SUPPLIERS' direct SUBSTANCE MANUFACTURER) to MERCK (or its AFFILIATE(S) or THIRD PARTY SUPPLIER(S)) as a SUBSTANCE MANUFACTURER, MERCK shall pay CODEXIS $[***]. Notwithstanding the foregoing, if MERCK's, its AFFILIATES', or its THIRD PARTY SUPPLIERS' direct purchases from a SUBSTANCE MANUFACTURER are necessitated as the result of a supply issue as described in Section 2.1.2, CODEXIS waives its right to this $[***] payment.


[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

In the event that during any calendar year (N) MERCK’s, its AFFILIATES’, and its THIRD PARTY SUPPLIERS’ purchases from direct SUBSTANCE MANUFACTURER exceeds [***]% of MERCK’s SUBSTANCE demand in calendar year (N), thereby resulting in a CODEXIS share of less than [***]% for calendar year (N), then MERCK shall make up such deficit of purchases from CODEXIS in the following calendar year (N+1). Such make-up volume shall be in addition to the minimum of [***]% of SUBSTANCE demand MERCK, its AFFILIATES, and its THIRD PARTY SUPPLIERS are required to purchase from CODEXIS in calendar year (N+1). Make-up volume to be purchased in calendar year (N+1) will be priced according to the CUMULATIVE SUBSTANCE PURCHASE VOLUME TIER applicable on December 31 of calendar year (N).

For purposes of facilitating MERCK’s, its AFFILIATES’, and its THIRD PARTY SUPPLIERS’ acquisition of SUBSTANCE from [***], beginning February 1, 2022 CODEXIS will, upon request by MERCK, perform the following services (“ANCILLARY SERVICES”) for MERCK for each lot of SUBSTANCE purchased by MERCK, its AFFILIATES or its THIRD PARTY SUPPLIERS from [***] as contemplated by this Section 2.1.3:

1.Testing for Certificate of Analysis pursuant to the latest Quality Standard Specifications in effect per Section 6.1 and as provided for under Attachment 5 of the Agreement:

a.Color, Form and Appearance

b.Conversion/Specificity (@ 24 Hours)

c.LOD

d.Assay (Weight %)

e.Molecular Weight

f.SDS-PAGE - Identity

g.Use Test (@16 Hours)

2.QC analytical data review

3.QA review of QC data sheet

4.Processing of BSE/TSE and COA

5.Product release

MERCK shall pay to CODEXIS a fee of US$[***] for ANCILLARY SERVICES performed by CODEXIS for each lot of SUBSTANCE purchased by MERCK, its AFFILIATES or its THIRD PARTY SUPPLIERS from [***]. CODEXIS will invoice MERCK upon completion of the ANCILLARY SERVICES for each lot of SUBSTANCE. MERCK shall pay complete invoices in the same manner as set forth in Sections 9.1 and 9.2 of the Agreement. CODEXIS shall make available to MERCK during quality audits of CODEXIS all documentation generated by CODEXIS in the regular course of performing the ANCILLARY SERVICES. CODEXIS warrants that it shall perform such ANCILLARY SERVICES for MERCK in good faith and in the same manner and with the same level of care as CODEXIS performs such services for itself with respect to SUBSTANCE produced by [***] for CODEXIS. Except as provided in the preceding sentence, ANCILLARY SERVICES are provided “as-is, where-is,” and CODEXIS makes no warranty of any kind, express or implied, with respect to the ANCILLARY SERVICES including, without limitation, no warranties of merchantability, fitness for any particular purpose or conformance with industry standards. CODEXIS shall not discriminate against MERCK in the performance or timing of the ANCILLARY SERVICES as compared to its performance of similar services for CODEXIS’ own business, and CODEXIS shall not be required to discriminate against its own businesses in the performance of the ANCILLARY SERVICES for MERCK. All risk and liability associated with the use of any ANCILLARY SERVICES by MERCK, its AFFILIATES, its and their THIRD PARTY SUPPLIERS, and/or [***], and the use of any SUBSTANCE produced by [***] which is purchased by MERCK, its AFFILIATES and their THIRD PARTY SUPPLIERS from [***], is the sole responsibility of MERCK.”

1.03Section 2.2.1.1 shall be amended to read in its entirety as follows:

"Within five (5) business days at the beginning of each QUARTER during the TERM, MERCK shall provide CODEXIS in writing (e-mail is acceptable) a good faith forecast reflecting MERCK’s, its AFFILIATES', and its THIRD PARTY SUPPLIERS' requirements, if any, for SUBSTANCE for each of the following six (6) QUARTERS, including the QUARTER in which the forecast is delivered, by setting forth the quantities of SUBSTANCE to be supplied, broken down by QUARTER. All projected order dates, quantities and shipping dates set forth in the forecasts delivered pursuant to this Section 2.2.1.1 shall be binding on MERCK in respect of the requirements set forth for the next three (3) QUARTERS of the forecast, including the QUARTER in which the forecast is made. Additionally, for the third QUARTER of the binding forecast, during the ensuing QUARTER and up until the next QUARTER’s forecast, MERCK reserves the right to adjust the quantities forecasted for the third QUARTER of the binding forecast by up to and including ±[***] % without penalty. For example only, the January 5th forecast in any calendar year shall include binding forecasts for the QUARTERS commencing January 1, April 1,

-2-


[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

and July 1 in such calendar year and the binding forecast for the QUARTER commencing July 1 may be adjusted by ±[***] % without penalty between January 5th and April 5th. Except as provided in this Section 2.2.1.1, it is understood and agreed that the forecasts shall not constitute commitments to take DELIVERY of SUBSTANCE or FIRM ORDERS unless such forecasts are specified in writing by MERCK as binding."

1.04Section 2.2.1.6 shall be amended to read in its entirety as follows:

“CODEXIS shall cause each shipment of SUBSTANCE to be DELIVERED to MERCK with not less than [***] months of the then-current re-test period remaining on such shipment of SUBSTANCE; provided, however, that after the re-test period of SUBSTANCE is extended to [***] months or beyond, CODEXIS shall cause each shipment of SUBSTANCE to be DELIVERED to MERCK with not less than [***] months of the then-current re-test period remaining on such shipment of SUBSTANCE. CODEXIS will perform stability tests through at least [***] months.”

1.05Section 4.1.2.2 shall be amended to read in its entirety as follows:

“Subject to Section 9.1, MERCK shall pay CODEXIS a SUBSTANCE FEE for the purchase of SUBSTANCE according to the schedule in ATTACHMENT 3 (Revised July 1, 2021). The pricing set forth in ATTACHMENT 3 (Revised July 1, 2021) will apply through the remaining TERM of this AGREEMENT based on the current ≥[***] % SUBSTANCE LOADING FACTOR. The PARTIES agree to negotiate a new pricing table should MERCK reduce the current ≥[***] % SUBSTANCE LOADING FACTOR.

The PARTIES agree that such ATTACHMENT 3 (Revised July 1, 2021) shall apply equally to all FIRM ORDERS placed by MERCK, its AFFILIATES and its THIRD PARTY SUPPLIERS directly with CODEXIS for DELIVERY of SUBSTANCE under this Agreement.”

1.06Section 11.2 shall be amended to read in its entirety as follows:

“MERCK shall protect, defend, indemnify, and hold CODEXIS, its AFFILIATES and their respective REPRESENTATIVES, harmless from any and all LOSSES to the extent such LOSSES arise out of or result from: (i) any breach by MERCK and/or its AFFILIATES of their representations, warranties, covenants or obligations under this AGREEMENT; (ii) any negligence, recklessness, or willful misconduct by MERCK and/or its AFFILIATES; (iii) product liability related to the marketing, sale or use of any COMPOUND or PRODUCT, or (iv) the use by MERCK and/or its AFFILIATES and/or their THIRD PARTY SUPPLIERS of any ANCILLARY SERVICES provided by CODEXIS to such parties and/or [***] pursuant to Section 2.3. The indemnification obligations for items (i), (ii) and (iii) above shall not apply to the extent CODEXIS is required to indemnify MERCK and its REPRESENTATIVES in accordance with Section 11.1, and the indemnification obligations for item (iv) above shall not apply to the extent of CODEXIS’ or its REPRESENTATIVES’ gross negligence or willful misconduct.”

1.07Section 12.1 shall be amended to read in its entirety as follows:

"This AGREEMENT shall become effective as of February 1, 2012 and shall continue in effect until December 31, 2026. This AGREEMENT may be renewed for an additional five (5) year term (beginning January 1, 2027) upon mutual written agreement executed by both PARTIES. Both PARTIES agree to initiate negotiations in good faith no later than [***] to extend this AGREEMENT and, provided an extension is mutually agreed upon, reach a commercial agreement no later than [***] for the new contract period 2027-2031. Both PARTIES acknowledge the intent to renew the AGREEMENT once the SUBSTANCE price is mutually agreed upon, provided that business conditions have not been significantly altered for either or both PARTIES during the period between the AMENDMENT EFFECTIVE DATE of this AMENDMENT and the negotiation period defined above."

1.08Attachment 2 (Annual License Fee Schedule) shall be replaced with Exhibit A entitled “Attachment 2 (Revised July 1, 2021) Annual License Fee Schedule” to this AMENDMENT.

1.09Attachment 3 (Revised January 1, 2016) Substance Fees shall be replaced with Exhibit B entitled “Attachment 3 (Revised July 1, 2021) Substance Fees” to this AMENDMENT.

1.10The Parties also agree that in addition to the execution of this AMENDMENT to the AGREEMENT, the Parties will negotiate and enter into an Amended and Restated Sitagliptin Catalyst Supply Agreement (“AMENDED AND RESTATED AGREEMENT”) that will amend and supersede this AGREEMENT. This AMENDED AND RESTATED AGREEMENT will include the original AGREEMENT, all changes made to the AGREEMENT through the AMENDMENTS and any other changes deemed mutually agreeable between the Parties. The Parties agree to take commercially reasonable efforts to enter into this new AGREEMENT by [***].

2.Miscellaneous

-3-


[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

2.01Effect of AMENDMENT; Joinder. Except as expressly changed by this AMENDMENT, the AGREEMENT shall remain in full force and effect in accordance with its stated terms. The AGREEMENT and the Schedules and Exhibits thereto, as amended by this AMENDMENT and all preceding AMENDMENTS, set forth the entire understanding of the parties with respect to the subject matter thereof. There are no agreements, restrictions, promises, warranties, covenants or undertakings other than those expressly set forth or referred to therein. The AGREEMENT and the Schedules and Exhibits thereto, as amended by this AMENDMENT and all preceding AMENDMENTS, supersede all prior agreements and undertakings between the parties with respect to such subject matter.

2.02Counterparts. This AMENDMENT may be executed by the parties in separate counterparts, each of which when so executed and delivered is deemed an original. All such counterparts together constitute but one and the same instrument.

2.03Definitions. All capitalized terms used but not defined in this AMENDMENT shall have the respective definitions assigned to such terms in the AGREEMENT.

IN WITNESS WHEREOF, the parties have caused this AMENDMENT to be signed by their duly authorized representatives as of the date and year first written above.


Codexis, Inc.			Merck Sharp & Dohme Corp.


By: /s/ *John Nicols*			By: /s/ *Rajiv Sharma*
Name: John Nicols			Name: Rajiv Sharma
Title: President and Chief Executive Officer			Title: Director-Procurement
Date: August 16, 2021			Date: September 8, 2021

-4-


[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

Exhibit A:

ATTACHMENT 2 (REVISED JULY 1, 2021)

ANNUAL LICENSE FEE SCHEDULE


YEAR	DATE LICENSE FEE PAYABLE	LICENSE FEE IN MILLIONS USD
01	February 1, 2013	$ [***]
02	February 1, 2014	$ [***]
03	February 1, 2015	$ [***]
04	February 1, 2016	$ [***]
05	February 1, 2017	$ [***]
06	February 1, 2018	$ [***]
07	February 1, 2019	$ [***]
08	February 1, 2020	$ [***]
09	February 1, 2021	$ [***]

Note: For the avoidance of doubt, upon execution of this amendment, prior to November 1, 2021 no License Fee shall be due to CODEXIS from MERCK on [***].

-5-


[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

Exhibit B:

ATTACHMENT 3 (REVISED JULY 1, 2021)

SUBSTANCE FEE SCHEDULE

SUBSTANCE Price/Volume Table 1


CUMULATIVE SUBSTANCE PURCHASE VOLUME TIER [CUMULATIVE SUBSTANCE PURCHASE VOLUME delivered commencing January 1, 2017 through January 31, 2022 (kg)		SUBSTANCE PRICE AT ≥[***] % SUBSTANCE LOADING FACTOR ($/kg)
[***]	[***]	[***]

SUBSTANCE Price/Volume Table 2


CUMULATIVE SUBSTANCE PURCHASE VOLUME TIER [CUMULATIVE SUBSTANCE PURCHASE VOLUME delivered commencing February 1, 2022 and thereafter] (kg)		SUBSTANCE PRICE AT ≥[***] % SUBSTANCE LOADING FACTOR ($/kg)
[***]	[***]	[***]

Effective [***], 2022, in the event that [***], the parties shall make commercially reasonable efforts to negotiate in good faith [***]. [***]. In all cases, throughout the Term, CODEXIS shall [***], 20[***], [***].

-6-

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-Q’ Filing	Date	Other Filings

	1/1/27
	12/31/26
	2/1/22
	1/31/22
Filed on:	11/5/21
	11/1/21
For Period end:	9/30/21
	9/8/21
	8/16/21	4
	7/1/21
	2/1/21
	2/1/20
	2/1/19
	2/1/18
	2/1/17
	1/1/17
	2/1/16
	1/1/16
	12/4/15
	2/25/15
	2/1/15
	2/1/14
	10/1/13	8-K
	2/1/13
	2/1/12
		List all Filings

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/27/23  Codexis, Inc.                     10-K       12/31/22  121:15M
 2/28/22  Codexis, Inc.                     10-K       12/31/21  111:16M

2 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/04/12  Codexis, Inc.                     8-K:1,2,3,5 8/28/12    5:380K                                   Donnelley … Solutions/FA
 5/28/10  Codexis, Inc.                     10-Q        3/31/10    6:850K                                   Donnelley … Solutions/FA

↑Top

Filing Submission 0001200375-21-000056 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)